Objective The advent of personalized cancer care demands for distributed diagnostic solutions to support clinical decisions and selection of the best therapeutic regimen. Supportive information can be obtained by analyzing the response of patient’s tissue to various treatment options. A specific opportunity arises in the field of cellular analysis, where the ex-vivo assessment of drug efficacy performed through drug response assays represents a powerful tool and, at the same time, a challenge due to the difficulty of maintaining in-vitro conditions that closely resemble in-vivo cell response. CellPly developed a novel in-vitro diagnostic (IVD) product to define cell response to anti-cancer drug treatment through integrated drug response analyses. Oncosmart platform includes a smart consumable, integrating a hybrid polymer/flexible-PCB micro-technology, an analytical instrument and diagnostic software.After patient’s tissue sampling, an automated process will carry out sample preparation, precise drug delivery and monitoring of cell response through time-lapse imaging. Cancer patients will benefit from more personalized cancer therapies, while the public health systems will reduce overall analysis and hospitalization costs and better allocate resources dedicated to cancer therapies. The Phase 1 project will set up the a quality-certified manufacturing chain and plan the validation of the platform in clinical setting in the field of acute leukemia; regulatory pathways to comply with CE-IVD and to seek reimbursement will be assessed; the commercialization strategy and associated business model(s) will be elaborated. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoveryengineering and technologyother engineering and technologiesmicrotechnologylab on a chipmedical and health sciencesbasic medicineimmunologymedical and health scienceshealth sciencespersonalized medicinemedical and health sciencesclinical medicineoncologyleukemia Keywords Microfluidics Lab-on-a-chip Diagnostics Point-of-care Personalized Medicine Predictive Oncology medical device healthcare cancer leukemia in vitro chemotherapy drug testing bedside Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator CELLPLY SRL Net EU contribution € 50 000,00 Address VIA FONDAZZA 53 40125 Bologna Italy See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Nord-Est Emilia-Romagna Bologna Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
